Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Cassava Sciences Back in the Game?

TheMotleyFool

0 0

Last week, biotech Cassava Sciences (NASDAQ: SAVA) published topline interim-analysis data for simufilam, a potential treatment for Alzheimer's disease. This is the company's sole late-stage candidate. The stock surged over 20% in pre-market trading on the news Wednesday, only to lose all of its gains and then some. The stock closed Wednesday down 1% to $52.31 and traded up over 23% on Friday to $64.40.

The company was recently hit by allegations from short-sellers, so it needed an opportunity like this to defend itself. Unfortunately, these developments do not paint a clear path to victory, but instead, they raise more perplexing questions about its science. Let's find out why.

Image source: Getty Images.

Source Fool.com

Like: 0

SAVA

Share